Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 229

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

PI3K inhibitors as new cancer therapeutics: implications for clinical trial design

Open access
Massacesi, Cristian, Di Tomaso, Emmanuelle, Urban, Patrick, Germa, Caroline, Quadt, Cornelia, Trandafir, Lucia, Aimone, Paola, Fretault, Nathalie, Dharan, Bharani, Tavorath, Ranjana, Hirawat, Samit·2016·OncoTargets and Therapy

Abstract

The PI3K-AKT-mTOR pathway is frequently activated in cancer. PI3K inhibitors, including the pan-PI3K inhibitor buparlisib (BKM120) and the PI3Kα-selective inhibitor alpelisib (BYL719), currently in clinical development by Novartis Oncology, may therefore be effective as anticancer agents. Early clinical studies with PI3K inhibitors have demonstrated preliminary antitumor activity and acceptable safety profiles. However, a number of unanswered questions regarding PI3K inhibition in cancer remain, including: what is the best approach for different tumor types, and which biomarkers will accurately identify the patient populations most likely to benefit from specific PI3K inhibitors? This review summarizes the strategies being employed by Novartis Oncology to help maximize the benefits of clinical studies with buparlisib and alpelisib, including stratification according to PI3K pathway activation status, selective enrollment/target enrichment (where patients with PI3K pathway-activated tumors are specifically recruited), nonselective enrollment with mandatory tissue collection, and enrollment of patients who have progressed on previous targeted agents, such as mTOR inhibitors or endocrine therapy. An overview of Novartis-sponsored and Novartis-supported trials that are utilizing these approaches in a range of cancer types, including breast cancer, head and neck squamous cell carcinoma, non-small cell lung carcinoma, lymphoma, and glioblastoma multiforme, is also described.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2147/ott.s89967

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 229

Metadata

Authors
Massacesi, C., Di Tomaso, E., Urban, P., Germa, C., Quadt, C., Trandafir, L., Aimone, P., Fretault, N., Dharan, B., Tavorath, R., & Hirawat, S.
Venue
OncoTargets and Therapy
Published
2016-01
Volume
9
Pages
203
ISSN
1178-6930 (ISSN-L)
OpenAlex
W2229509093
Cited by
229
References
3
FWCI
21.52
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PI3K inhibitors as new cancer therapeutics: implications for clinical trial design. https://app.cochat.ai/papers/10.2147/ott.s89967
The paper
Massacesi, C., Di Tomaso, E., Urban, P., Germa, C., Quadt, C., Trandafir, L., Aimone, P., Fretault, N., Dharan, B., Tavorath, R., & Hirawat, S. (2016). PI3K inhibitors as new cancer therapeutics: implications for clinical trial design. OncoTargets and Therapy. https://doi.org/10.2147/ott.s89967

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.